Endocrine Society's Annual Meeting to Feature Data on VIVUS' Qnexa

Update: Qsymia (phentermine/topiramate) Now FDA Approved - July 17, 2012

 

MOUNTAIN VIEW, Calif., June 16 /PRNewswire-FirstCall/ -- VIVUS, Inc. (NASDAQ:VVUS) today announced that data on Qnexa®, an investigational drug candidate, will be presented at the Endocrine Society's 92nd Annual Meeting and Expo (ENDO) in San Diego, California. Timothy Garvey, M.D., professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham and a Qnexa investigator, will deliver an oral presentation at the Clinical Trials Symposium on Saturday, June 19, entitled: "Once-Daily, Low-Dose, Controlled-Release Phentermine/Topiramate Demonstrates Significant Improvement in Weight, Related Risk in Overweight/Obese Patients with Comorbidities."
 

"We are pleased to have a significant presence at this year's ENDO meeting, where Dr. Timothy Garvey will present data that further illustrate the potential impact that Qnexa, if approved, may have on life-threatening weight-related comorbidities, including cholesterol, blood pressure and diabetes," stated Wesley Day, PhD, vice president, clinical development at VIVUS. "We look forward to sharing these important data with our colleagues in the endocrinology community."
 

  Following are details about the upcoming presentation:

  The Endocrine Society's 92nd Annual Meeting and Expo, San Diego, Calif.

  Date and Time: Saturday, June 19, 2010, 3:45-4 PM PDT
  Session: Clinical Trials Symposium
  Abstract: S19-5

Presentation Title: Once-Daily, Low-Dose, Controlled-Release Phentermine/Topiramate Demonstrates Significant Improvement in Weight, Related Risk in Overweight/Obese Patients with Comorbidities
 

  Location:  Room 29ABC, San Diego Convention Center
  Presenter: W. Timothy Garvey, M.D.

  About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead product in clinical development, Qnexa®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.
 

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2009 and periodic reports filed with the Securities and Exchange Commission.
 

  CONTACT:
  --------

  VIVUS, Inc.                   Investor Relations: The Trout Group
  Timothy E. Morris             Brian Korb
  Chief Financial Officer       646-378-2923
  650-934-5200
                                Media Relations: Pure Communications, Inc.
                                Dan Budwick
                                973-271-6085

Source: VIVUS, Inc.

CONTACT: Timothy E. Morris, Chief Financial Officer of VIVUS, Inc.,
+1-650-934-5200; or Investors, Brian Korb of The Trout Group, +1-646-378-2923;
or Media, Dan Budwick of Pure Communications, Inc., +1-973-271-6085, both for
VIVUS, Inc.
 

Web Site: http://www.vivus.com/
 

Posted: June 2010

View comments

Hide
(web3)